Kalaris Therapeutics (KLRS) Earnings Analysis

Kalaris Therapeutics (KLRS) next reports earnings on 2026-08-12, consensus EPS -0.5 USD. Last quarter (2026-03-17) it beat with EPS -0.44 USD vs -0.56 USD est (+21.4%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -1.89.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does KLRS next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate-0.5 USD
Revenue estimaten/a

KLRS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-17-0.44 USD-0.56 USD+21.4%Beat
2025-08-13-0.61 USD-0.51 USD-19.6%Miss
2025-05-14-2.52 USD-0.78 USD-223.1%Miss
2025-03-07-3.63888 USD-2.76 USD-31.8%Miss

Beat rate: 1/4 (25%) over reported quarters with consensus data.

KLRS valuation and analyst view

Trailing P/E-1.89
Trailing EPS-1.85882 USD
Price / book1.41
Dividend yield0.00%
Market cap0.07B
Analyst consensusBuy (1 buy / 0 hold / 0 sell)
Avg price target17 USD

Related research pages

Frequently asked questions

When is Kalaris Therapeutics (KLRS)'s next earnings date?

Kalaris Therapeutics is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.5 USD.

Did KLRS beat earnings last quarter?

In its 2026-03-17 report, KLRS posted EPS of -0.44 USD versus a -0.56 USD estimate — a beat of 21.4%.

What is KLRS's earnings track record?

Over the last 4 reported quarters with consensus data, KLRS beat estimates 1 times (25%).

What is KLRS's current P/E ratio and EPS?

KLRS trades at a trailing P/E of -1.89 on trailing EPS of -1.8588227141408196 USD.

What do analysts rate KLRS?

Analyst consensus is "Buy" across 1 ratings (0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 17 USD.